With ongoing clinical trials on the combination of ICI and tocilizumab for malignant melanoma, urothelial carcinoma, and non-small cell lung cancer (NCT04940299), further studies are needed to clarify the optimal timing, dosing, and integration of IL-6 blockade in ICI-based regimens. This evidence concerns the gene IL6 and urothelial carcinoma.